A detailed history of Algert Global LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 25,730 shares of SAGE stock, worth $277,369. This represents 0.02% of its overall portfolio holdings.

Number of Shares
25,730
Previous 25,730 -0.0%
Holding current value
$277,369
Previous $558,000 13.62%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$17.1 - $22.26 $529,416 - $689,169
-30,960 Reduced 54.61%
25,730 $558,000
Q3 2023

Nov 13, 2023

BUY
$16.75 - $48.98 $949,557 - $2.78 Million
56,690 New
56,690 $1.17 Million
Q1 2023

May 12, 2023

SELL
$37.27 - $46.57 $403,894 - $504,679
-10,837 Reduced 43.15%
14,280 $599,000
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $274,344 - $371,557
-8,520 Reduced 25.33%
25,117 $958,000
Q3 2022

Nov 15, 2022

SELL
$32.28 - $43.27 $1.26 Million - $1.69 Million
-39,112 Reduced 53.76%
33,637 $1.32 Million
Q2 2022

Aug 15, 2022

BUY
$27.52 - $37.99 $1.49 Million - $2.05 Million
54,077 Added 289.62%
72,749 $2.35 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $377,610 - $562,050
12,296 Added 192.85%
18,672 $618,000
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $38,542 - $48,994
1,040 Added 19.49%
6,376 $271,000
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $214,827 - $306,126
5,336 New
5,336 $236,000
Q1 2021

May 14, 2021

SELL
$70.65 - $96.76 $516,451 - $707,315
-7,310 Closed
0 $0
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $1.23 Million - $1.88 Million
-21,121 Reduced 74.29%
7,310 $632,000
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $1.18 Million - $1.79 Million
-28,727 Reduced 50.26%
28,431 $1.74 Million
Q2 2020

Aug 12, 2020

BUY
$25.95 - $43.15 $607,022 - $1.01 Million
23,392 Added 69.28%
57,158 $2.38 Million
Q1 2020

May 13, 2020

BUY
$26.15 - $77.24 $882,980 - $2.61 Million
33,766 New
33,766 $970,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $641M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.